The U.S. Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN) launch the Artificial Kidney Prize Phase 2
$10.5 million is available for up to nine winners in two tracks.
$10.5 million is available for up to nine winners in two tracks.
Their device uses a unique molecule (LXW7) that promotes the binding of endothelial cells to synthetic grafts.
The Center for Devices and Radiological Health (CDRH) at the Food and Drug Administration (FDA) has granted its novel technology, the SelfWrap® Bioabsorbable Perivascular Wrap, Breakthrough Device Designation (BDD).
Alio Inc. is developing a technology to monitor ESKD patients undergoing hemodialysis.
KHI is releasing a draft version of its Human-Centered Design Toolkit for Kidney Failure for public comment. The toolkit provides pre-clinical innovators and early-stage start-ups developing kidney replacement therapies with empathy tools to facilitate their interactions with people with kidney failure, enable market segmentation, and provide a framework for a customer requirements document.
KidneyX's Redesign Dialysis Phase 2 winner Relavo, Inc. received $1M from the National Science Foundation Small Business Innovation Research (SBIR) grant.
The U.S. Ambassador Joseph Cella hosted Pacific health officials and clinicians for a dialogue on the prevention, diagnosis, and treatment of kidney disease. The conversation generated ideas and inspiration for new ways that the United States, Fiji, and other Pacific island countries can work together to overcome health challenges.
Timothy Bouré and his co-founder Geoffrey Lucks were both near broke when they moved to Dallas to join the first accelerator they entered after forming VenoStent, a company that aims to improve outcomes for dialysis patients.
The award will support them as they work full-time on a solution for safer at-home dialysis—an issue they'll meet with greater urgency as the coronavirus pandemic makes in-person treatment riskier
A major award could provide new hope to thousands of kidney patients in the U.S., and possibly, freedom from undergoing traditional dialysis.
There are no upcoming events at this time.